| 1 |
NCT03491202 |
Recruiting |
The Genetic Basis for Atrial Fibrillation |
|
|
Observational
|
|
- Jesse Brown VA Medical Center
|
U.S. Fed |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Symptoms related to atrial fibrillation (chest pain, dyspnea, palpitations)
- heart rate
|
600 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT03491202 |
977544 |
|
May 25, 2017 |
May 2022 |
May 2022 |
April 9, 2018 |
June 11, 2018 |
|
- Jesse Brown VA Medical Center
Chicago, Illinois, United States
|
|
| 2 |
NCT02710669 |
Recruiting |
New Formulations of Propafenone to Treat Atrial Fibrillation |
|
- Drug: (R)-propafenone
- Drug: (S)-Propafenone
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Vanderbilt University
- National Heart, Lung, and Blood Institute (NHLBI)
- Vanderbilt University Medical Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Induction of atrial fibrillation (yes or no)
|
243 |
All |
18 Years and older (Adult, Older Adult) |
NCT02710669 |
151952
1R01HL124935-01A1 |
|
October 2016 |
March 2020 |
March 2020 |
March 17, 2016 |
September 28, 2018 |
|
- Vanderbilt University
Nashville, Tennessee, United States
|
|
| 3 |
NCT03628534 |
Recruiting |
Saline Enhanced Radiofrequency (SERF) VT Ablation Early Feasibility Study (EFS) |
- Ventricular Tachycardia
- Arrythmia
- Heart Diseases
- Cardiovascular Diseases
|
- Device: Saline Enhanced Radiofrequency (SERF) ablation
|
Interventional
|
Not Applicable |
- Thermedical, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
|
Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- EFFICACY: Non-inducibility of the targeted clinical VT at end of ablation procedure.
- SAFETY: Serious adverse events that are probably or definitely device related related
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03628534 |
CP-100
R44HL132746 |
SERF VT EFS |
November 8, 2018 |
September 2019 |
December 2019 |
August 14, 2018 |
November 16, 2018 |
|
- Loyola University Medical Center
Maywood, Illinois, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 4 |
NCT03082963 |
Recruiting |
Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation |
|
- Device: Electrogram Morphology Mapping (EMR)
|
Interventional
|
Not Applicable |
- Jeffrey Goldberger
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Miami
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Real-time electrogram morphology recurrence mapping feasibility
- Ablation Acute Effects
- 30-day post ablation treatment emergent adverse events
|
10 |
All |
21 Years and older (Adult, Older Adult) |
NCT03082963 |
20150757
1R41HL127907-01A1 |
|
April 4, 2017 |
December 31, 2018 |
December 31, 2018 |
March 17, 2017 |
October 17, 2018 |
|
- University of Miami
Miami, Florida, United States
|
|
| 5 |
NCT03327623 |
Recruiting |
Sleep Apnea and Hypertrophic Cardiomyopathy (HCM) |
- Hypertrophic Cardiomyopathy
|
|
Observational
|
|
- Mayo Clinic
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Prevalence of Obstructive Sleep Apnea (OSA).
- Determine the severity of Sleep Apnea.
- Differences in Autonomic Regulation.
- (and 5 more...)
|
662 |
All |
18 Years and older (Adult, Older Adult) |
NCT03327623 |
17-003514 16-009474
1R01HL134885-01
FP00093543 |
|
November 13, 2017 |
June 2021 |
June 2025 |
October 31, 2017 |
March 6, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 6 |
NCT00409435 |
Recruiting |
A Study of Pyridostigmine in Postural Tachycardia Syndrome |
- Postural Tachycardia Syndrome
|
- Drug: pyridostigmine
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Mayo Clinic
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in orthostatic symptoms using Composite Autonomic Symptom Scale (COMPASS) change
- Heart rate response to head-up tilt
- Plasma norepinephrine change
|
50 |
All |
15 Years to 55 Years (Child, Adult) |
NCT00409435 |
06-002442 |
|
October 2006 |
February 2019 |
February 2019 |
December 8, 2006 |
April 13, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 7 |
NCT03228823 |
Not yet recruiting |
Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS) |
- Ventricular Premature Beats, Contractions, or Systoles
- Cardiomyopathies
|
- Procedure: Radiofrequency ablation
- Drug: Amiodarone (Antiarrhythmic drug)
|
Interventional
|
Phase 4 |
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Virginia Commonwealth University
- University of California, San Francisco
- (and 3 more...)
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement of left ventricular ejection fraction after PVC suppression
- Responders to PVC suppression strategy
- Successful PVC suppression
- (and 2 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03228823 |
NIH ID 9372611
R34HL138110-01 |
PAPS |
September 1, 2017 |
August 31, 2020 |
August 31, 2020 |
July 25, 2017 |
July 27, 2017 |
|
- University of California, San Francisco
San Francisco, California, United States - McGuire VA Medical Center
Richmond, Virginia, United States - Virginia Commonwealth University
Richmond, Virginia, United States - Libin Cardiovascular Institute, University of Calgary
Calgary, Alberta, Canada
|
|
| 8 |
NCT02169037 |
Recruiting |
Substrate Versus Trigger Ablation for Paroxysmal Atrial Fibrillation |
|
- Procedure: FIRM Ablation
- Procedure: Conventional AF ablation with PVI
|
Interventional
|
Not Applicable |
- University of California, San Diego
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Long term success
- Long-term freedom from AF/AT
- Total ablation time
- (and 3 more...)
|
120 |
All |
21 Years and older (Adult, Older Adult) |
NCT02169037 |
NAR083359
R01HL083359 |
SUBSTRATE |
February 2016 |
September 2020 |
September 2021 |
June 20, 2014 |
March 3, 2016 |
|
- Stanford University
Palo Alto, California, United States - VA San Diego Medical Center
San Diego, California, United States
|
|
| 9 |
NCT03519360 |
Not yet recruiting |
Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B |
|
- Other: UFR-restricted dialysis
- Other: UFR-unrestricted dialysis
|
Interventional
|
Phase 2 |
- Brigham and Women's Hospital
- National Institutes of Health (NIH)
- Duke University
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Adherence with Proposed Interventions
- Incidence of unscheduled hemodialysis or hospitalization for volume overload
- Change in duration of clinically significant arrhythmia (CSA) per month
- (and 8 more...)
|
20 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03519360 |
2017P001737-
R34HL140477-01 |
RADAR-B |
July 1, 2018 |
July 1, 2020 |
July 1, 2021 |
May 9, 2018 |
May 9, 2018 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
|
| 10 |
NCT03261570 |
Recruiting |
Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS |
- Postural Orthostatic Tachycardia Syndrome (POTS)
- POTS
- Orthostatic Intolerance
|
- Drug: Pyridostigmine
- Drug: Digoxin
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
- New York Medical College
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Cardiovagal Baroreflex during orthostatic stress
- Cognitive ability during orthostatic stress
- Cardiac output measure by inert gas breathing technique
- (and 3 more...)
|
80 |
Female |
15 Years to 30 Years (Child, Adult) |
NCT03261570 |
1R01HL134674-01A1 |
|
July 1, 2017 |
June 30, 2021 |
September 1, 2021 |
August 25, 2017 |
July 19, 2018 |
|
- New York Medical College/Bradhurst building
Hawthorne, New York, United States
|
|
| 11 |
NCT03498729 |
Recruiting |
Autoimmunity in the Pathogenesis of AF |
|
- Other: Peripheral Blood Sample
|
Observational
|
|
- Mayo Clinic
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
|
240 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03498729 |
16-005678
1K01HL135288-01 |
|
March 5, 2018 |
December 31, 2021 |
December 31, 2021 |
April 17, 2018 |
April 17, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 12 |
NCT03093051 |
Not yet recruiting |
Termination Therapy for Ventricular Tachyarrhythmias |
- Ventricular Fibrillation
- Ventricular Tachycardia
|
- Other: Unpinning Termination therapy
|
Observational
|
|
- Cardialen, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- Washington University School of Medicine
|
Industry / NIH / Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Arrhythmia Termination as assessed by the number of episodes restored to sinus rhythm
|
50 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03093051 |
CL005 |
JUPITER |
November 2018 |
November 2020 |
February 2021 |
March 28, 2017 |
April 17, 2018 |
|
|
|
| 13 |
NCT03519347 |
Not yet recruiting |
Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A |
|
- Other: Potassium Removal Maximization
- Other: Potassium Gradient Minimization
- Other: Alkalosis Avoidance
- Other: Acidosis avoidance
|
Interventional
|
Phase 2 |
- Brigham and Women's Hospital
- National Institutes of Health (NIH)
- Duke University
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Adherence with Proposed Interventions
- Recruitment feasibility
- Incidence of severe potassium abnormalities
- (and 12 more...)
|
20 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03519347 |
2017P001737
R34HL140477-01 |
RADAR-A |
July 1, 2018 |
July 1, 2020 |
July 1, 2021 |
May 9, 2018 |
May 15, 2018 |
|
- Duke University School of Medicine
Durham, North Carolina, United States
|
|
| 14 |
NCT00608725 |
Recruiting |
Pathophysiology of Orthostatic Intolerance |
- Tachycardia
- Postural Orthostatic Tachycardia Syndrome
|
- Radiation: DAXOR
- Procedure: QSweat
- Drug: Intrinsic Heart Rate
|
Interventional
|
Not Applicable |
- Satish R. Raj
- National Institutes of Health (NIH)
- Vanderbilt University Medical Center
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Physiological abnormalities in orthostatic intolerance
- blood volume
- intrinsic heart rate
- (and 3 more...)
|
100 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00608725 |
8398
NIH HL56693 |
|
December 1996 |
December 2019 |
December 2019 |
February 6, 2008 |
August 10, 2018 |
|
- Vanderbilt University
Nashville, Tennessee, United States
|
|
| 15 |
NCT03493516 |
Recruiting |
Prediction of ARrhythmic Events With Positron Emission Tomography II |
- Sudden Cardiac Arrest
- Ischemic Cardiomyopathy
- Congestive Heart Failure
|
- Diagnostic Test: PET scan quantifying sympathetic denervation using [18F]-LMI1195
|
Observational
|
|
- State University of New York at Buffalo
- National Heart, Lung, and Blood Institute (NHLBI)
- Lantheus Medical Imaging
|
Other / NIH / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Sudden Cardiac Arrest Events
|
302 |
All |
18 Years and older (Adult, Older Adult) |
NCT03493516 |
HL-130266
R01HL130266-01 |
PAREPET II |
April 8, 2018 |
December 31, 2022 |
December 31, 2023 |
April 10, 2018 |
April 10, 2018 |
|
- University at Buffalo Clinical and Translational Research Center
Buffalo, New York, United States
|
|
| 16 |
NCT03441022 |
Not yet recruiting |
Continuous Data Collection and Analysis for Stroke Prevention Using a Wearable Sensor |
|
- Device: Amiigo Watch Only
- Device: Amiigo Watch + BodyGuardian
|
Interventional
|
Not Applicable |
- Mayo Clinic
- Koronis Biomedical Technologies
- National Institute on Aging (NIA)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Watch Accuracy during Cardioversion
- Watch Accuracy compared to BodyGuardian
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03441022 |
17-006346
1R43AG058516-01 |
|
August 2018 |
August 2020 |
August 2020 |
February 21, 2018 |
February 21, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
|
| 17 |
NCT03634072 |
Recruiting |
Pediatric REPlAcement of the PulmonaRy ValvE in Tetralogy of Fallot - |
|
|
Interventional
|
Not Applicable |
- Children's Hospital of Philadelphia
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Operational feasibility of a randomized multicenter trial
- Exercise performances
- Prevalence of arrhythmias
- (and 4 more...)
|
100 |
All |
13 Years to 21 Years (Child, Adult) |
NCT03634072 |
18-015046
R34HL142142-01 |
TOFandPVR |
July 6, 2018 |
August 1, 2021 |
August 1, 2021 |
August 16, 2018 |
August 16, 2018 |
|
- The Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 18 |
NCT03333161 |
Recruiting |
Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 2 |
|
- Diagnostic Test: Cardiorespiratory monitoring
|
Interventional
|
Not Applicable |
- University of Alabama at Birmingham
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hypoxemic episode
- Bradycardic episode
- Apnea episodes
- (and 2 more...)
|
25 |
All |
up to 15 Days (Child) |
NCT03333161 |
UAB Neo 017
U01HL133536 |
|
April 4, 2018 |
May 30, 2020 |
December 30, 2020 |
November 6, 2017 |
April 9, 2018 |
|
- Regional Neonatal ICU and CCN, University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 19 |
NCT02549664 |
Recruiting |
Exercise in Genetic Cardiovascular Conditions |
- Hypertrophic Cardiomyopathy
- Long QT Syndrome
|
|
Observational
|
|
- Yale University
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Composite risk of death, cardiac arrest, ventricular arrhythmias, or syncope in individuals with HCM or LQTS who are participating in moderate or vigorous exercise and in sedentary individuals.
- Emotional Quality of Life assessed using Pediatric Cardiac Quality of Life Inventory (Pcqli)
- Physical Quality of Life assessed using Pediatric Quality of Life Inventory (PedsQL)
- Physical Quality of Life assessed using Health Status Questionnaire (SF36) Quality of Life for Adults
|
4286 |
All |
8 Years to 60 Years (Child, Adult) |
NCT02549664 |
1411014982
1R01HL125918-01 |
LIVE-HCM/LQT |
May 2015 |
May 2018 |
May 2020 |
September 15, 2015 |
October 18, 2017 |
|
- University of Arizona
Tucson, Arizona, United States - Cedar Sinai/LA Cardiology
Los Angeles, California, United States - University of California Irvine
Orange, California, United States - (and 36 more...)
|
|
| 20 |
NCT03436082 |
Recruiting |
Post-Market Surveillance With a Novel mHealth Platform |
- Gastrectomy
- Atrial Fibrillation
|
- Device: A mobile health platform
|
Observational
|
|
- Yale University
- Johnson & Johnson
- Food and Drug Administration (FDA)
- Mayo Clinic
|
Other / Industry / U.S. Fed |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Enrollment time after a sleeve gastrectomy or gastric bypass
- Enrollment time catheter-base atrial fibrilation
- Patient participation - sleeve gastrectomy or gastric bypass
- (and 6 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03436082 |
2000021455 |
|
January 26, 2018 |
August 31, 2018 |
August 31, 2018 |
February 16, 2018 |
March 29, 2018 |
|
- Yale New Haven Hospital
New Haven, Connecticut, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 21 |
NCT03508934 |
Recruiting |
Continuous Glucose Monitoring Devices in Hospitalized Veterans With Diabetes |
- Diabetes Mellitus, Type 2
- Hypoglycemia
|
- Device: GTS (Continuous Glucose Monitoring)
- Other: POC (Point of Care)
|
Interventional
|
Phase 2
Phase 3 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Decrease in hypoglycemia during the hospitalization
|
244 |
All |
21 Years and older (Adult, Older Adult) |
NCT03508934 |
ENDA-022-17F
CX001825-01 |
|
July 1, 2018 |
June 30, 2022 |
June 30, 2023 |
April 26, 2018 |
July 17, 2018 |
|
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Baltimore, Maryland, United States
|
|
| 22 |
NCT02907476 |
Recruiting |
The Treatment of Depression With Yoga and Walking |
- Depression
- Major Depressive Disorder
- PTSD
- Anxiety
|
- Behavioral: Iyengar Yoga
- Behavioral: Walking
|
Interventional
|
Not Applicable |
- Boston University
- Partners HealthCare
- National Center for Complementary and Integrative Health (NCCIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Brain gamma amino-butyric acid (GABA) levels (change will be measured)
- Beck Depression Index Inventory (BDI-II)
- Spielberger State-Trait Anxiety Inventory (STAI)
- (and 6 more...)
|
900 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02907476 |
H-34681
5R01AT007483-05 |
|
January 4, 2017 |
July 30, 2019 |
July 30, 2019 |
September 20, 2016 |
June 6, 2018 |
|
- Solomon Carter Fuller Building
Boston, Massachusetts, United States
|
|
| 23 |
NCT01758692 |
Recruiting |
Measurement of Autonomic Cardiovascular Integrity in Persons With SCI |
|
|
Observational
|
|
- James J. Peters Veterans Affairs Medical Center
|
U.S. Fed |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Autonomic Classification
- Edrophonium chloride as a test of cardio-vagal receptor integrity at the sinoatrial (SA) node
- Glycopyrrolate as a test of cardio-vagal efferent integrity
- (and 3 more...)
|
100 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT01758692 |
WEC-12-06
01436 |
|
July 2012 |
June 2021 |
June 2021 |
January 1, 2013 |
February 1, 2018 |
|
- James J Peters VA Medical Center
Bronx, New York, United States
|
|
| 24 |
NCT03387735 |
Recruiting |
Multiple Chronic Conditions for Older Adults |
|
- Other: Treatment as usual (TAU) + Internet
- Behavioral: TAU + C-CHESS
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
- University of Wisconsin Hospital and Clinics (UW Health)
- Medical University of South Carolina
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Health outcomes
- Healthcare use
- Chronic condition outcome: Hypertension
- (and 3 more...)
|
330 |
All |
65 Years and older (Older Adult) |
NCT03387735 |
2017-0849 |
|
January 1, 2018 |
June 2021 |
June 2021 |
January 2, 2018 |
February 20, 2018 |
|
- UW Health Clinics
Madison, Wisconsin, United States
|
|
| 25 |
NCT03420833 |
Recruiting |
Metabolic Mapping and Cardiac Resynchronization |
|
- Device: Cardiac resynchronization therapy pacemaker (CRT-P)
|
Interventional
|
Not Applicable |
- Yong-Mei Cha
- National Heart, Lung, and Blood Institute (NHLBI)
- Biotronik SE & Co. KG
- Mayo Clinic
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Change in Left Ventricle End-Systolic Volume Index (LVESVI)
- Number of Subjects Not Experiencing Any System-Related Complications
- Number of Subjects Admitted to the Hospital for Heart Failure
- (and 4 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03420833 |
17-003359
1R01HL134864-01A1 |
|
August 20, 2018 |
December 2021 |
December 2022 |
February 2, 2018 |
September 28, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
|
| 26 |
NCT03012022 |
Recruiting |
Cleveland Heart and Metabolic Prevention Study |
- Heart Failure Risk Factors in Healthy Individuals
|
|
Observational
|
|
- The Cleveland Clinic
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
- Correlation between metabolic and/or nitrative stress markers and predefined clinical endpoints
- Determination of sub-clinical myocardial dysfunction by echocardiogram
- Correlation between functional capacity, as measured by DASI questionnaire, and markers of metabolic and nitrative stress
- (and 3 more...)
|
2000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03012022 |
10-727
1R01HL103931 |
CHAMPS |
November 2010 |
December 2019 |
December 2019 |
January 6, 2017 |
January 26, 2018 |
|
- Cleveland Clinic
Cleveland, Ohio, United States
|
|
| 27 |
NCT00733590 |
Recruiting |
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention |
- Heart Failure, Congestive
- Death, Sudden, Cardiac
- Arrhythmia
- Cardiomyopathies
|
|
Observational
|
|
- Johns Hopkins University
- University of Maryland
- Washington Hospital Center
- (and 2 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Arrhythmic Sudden Death defined as a therapy from the ICD for rapid VT or VF or a ventricular arrhythmia not corrected by the ICD
- All cause mortality, CV mortality, heart transplant, LVAD, and ICD explantation or ICD Disabled
|
1500 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT00733590 |
NA_00045142
5R01HL091062 |
PROSe-ICD |
June 2003 |
March 2020 |
March 2020 |
August 13, 2008 |
August 16, 2018 |
|
- Washington Hospital Center
Washington, District of Columbia, United States - University of Maryland Medical Center
Baltimore, Maryland, United States - Johns Hopkins University School of Medicine
Baltimore, Maryland, United States - Virginia Commonwealth University School of Medicine
Richmond, Virginia, United States
|
|
| 28 |
NCT03340727 |
Not yet recruiting |
Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial |
|
- Drug: Caffeine Citrate
- Drug: Placebo
|
Interventional
|
Phase 3 |
- NICHD Neonatal Research Network
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of days of hospitalization
- The number of days to physiologic maturity after randomization
- PMA at discharge
- (and 12 more...)
|
1200 |
All |
29 Weeks to 33 Weeks (Child) |
NCT03340727 |
NICHD-NRN-0056
UG1HD034216
UG1HD027904
UG1HD021364
UG1HD027853
UG1HD040689
UG1HD040492
UG1HD027851
UG1HD087229
UG1HD053109
UG1HD068278
UG1HD068244
UG1HD068263
UG1HD027880
UG1HD053089
UG1HD087226
U10HD036790 |
MoCHA |
October 2018 |
October 2022 |
October 2022 |
November 13, 2017 |
June 29, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Stanford University
Palo Alto, California, United States - Emory University
Atlanta, Georgia, United States - (and 13 more...)
|
|
| 29 |
NCT01013714 |
Not yet recruiting |
Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias |
- Sudden Cardiac Death
- Ventricular Tachycardia
- Ventricular Fibrillation
- Cardiomyopathy
|
- Procedure: Cardiac Sympathetic Denervation (CSD)
- Drug: Routine Care
|
Interventional
|
Phase 3 |
- University of California, Los Angeles
- University of Alabama at Birmingham
- Johns Hopkins University
- (and 3 more...)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Time to any ICD shock or sustained VT (> 30 sec)
- Number of ICD shocks or sustained VT (below ICD detection, but in monitor zone) > 30 sec
- Number of appropriate ICD therapies (including ATPs )
- (and 6 more...)
|
172 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01013714 |
UCLA09-07-100-01 |
PREVENT VT |
July 2019 |
July 2024 |
July 2024 |
November 16, 2009 |
October 17, 2018 |
|
- UCLA Health
Los Angeles, California, United States
|
|
| 30 |
NCT01431326 |
Recruiting |
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care |
- Adenovirus
- Anesthesia
- Anxiety
- (and 47 more...)
|
- Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
|
Observational
|
|
- Daniel Benjamin
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- The EMMES Corporation
- Duke University
|
Other / NIH / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Composite of pharmacokinetic outcomes for understudied drugs in children
- Composite pharmacodynamic outcomes of understudied drugs in children
- Biomarkers associated with understudied drugs in children
|
10000 |
All |
up to 21 Years (Child, Adult) |
NCT01431326 |
Pro00029638
IND 113645
IND 114369
IND 114531
IND 118358
HHSN20100006
HHSN27500020
HHSN27500027
HHSN27500043
HHSN27500049 |
PTN_POPS |
November 2011 |
February 2020 |
February 2020 |
September 9, 2011 |
April 4, 2018 |
|
- Alaska Native Medical Center
Anchorage, Alaska, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - University of California at San Diego Medical Center
La Jolla, California, United States - (and 51 more...)
|
|
| 31 |
NCT03229941 |
Recruiting |
Transfusion Trigger After Operations in High Cardiac Risk Patients |
- Myocardial Infarction
- Coronary Revascularization
- Acute Renal Failure
|
- Procedure: Blood Transfusion
|
Interventional
|
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Other
|
- A composite endpoint of postoperative infectious complications at 90 days post-randomization: Infectious complications will include wound infections, pneumonia, and sepsis.
- A composite endpoint of cardiac complications (other than MI) at 90 days post-randomization: Cardiac complications will include new cardiac arrhythmias that necessitate new treatment, new or worsening congestive heart failure (CHF), and cardiac arrest no
- All-cause mortality at 1 year after randomization.
- (and 2 more...)
|
3070 |
All |
18 Years and older (Adult, Older Adult) |
NCT03229941 |
599 |
TOP |
February 5, 2018 |
February 28, 2022 |
February 28, 2022 |
July 26, 2017 |
October 5, 2018 |
|
- Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR
Little Rock, Arkansas, United States - North Florida/South Georgia Veterans Health System, Gainesville, FL
Gainesville, Florida, United States - James A. Haley Veterans' Hospital, Tampa, FL
Tampa, Florida, United States - (and 5 more...)
|
|
| 32 |
NCT01258231 |
Recruiting |
Identification of Genomic Predictors of Adverse Events After Cardiac Surgery |
- Heart; Dysfunction Postoperative, Cardiac Surgery
- Genetic Predisposition to Disease
- Atrial Fibrillation
- (and 2 more...)
|
|
Observational
|
|
- Brigham and Women's Hospital
- National Heart, Lung, and Blood Institute (NHLBI)
- Texas Heart Institute
- University of Texas Southwestern Medical Center
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Mortality (i.e. number of participants who are deceased during postoperative day 0 up to year 5)
|
4000 |
All |
20 Years to 90 Years (Adult, Older Adult) |
NCT01258231 |
2000P001639
5R01HL098601 |
CABGGenomics |
August 2000 |
August 2030 |
August 2030 |
December 10, 2010 |
September 20, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - UT Southwestern Medical Center
Dallas, Texas, United States - Department Texas Heart Institute at St. Luke's Episcopal Hospital
Houston, Texas, United States
|
|
| 33 |
NCT03530124 |
Recruiting |
Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines |
- Apnea
- Apnea Neonatal
- Prematurity
|
- Biological: PCV13
- Biological: DTaP
- Biological: HBV
- (and 2 more...)
|
Interventional
|
Phase 4 |
- Duke University
- Centers for Disease Control and Prevention
- Children's Hospital Medical Center, Cincinnati
- University of North Carolina
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Occurrence of Apnea
- Number of Apneic Episodes
- Duration of Apneic Episodes
- (and 2 more...)
|
300 |
All |
6 Weeks and older (Child, Adult, Older Adult) |
NCT03530124 |
Pro00088094
200 2012 53663 0010 |
|
July 17, 2018 |
October 31, 2020 |
November 14, 2020 |
May 21, 2018 |
September 12, 2018 |
|
- Centers for Disease Control and Prevention
Atlanta, Georgia, United States - University of North Carolina
Chapel Hill, North Carolina, United States - Duke University
Durham, North Carolina, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
|
| 34 |
NCT02154009 |
Recruiting |
Clinical Autonomic Disorders: A Training Protocol |
- Chronic Fatigue Syndrome
- Pseudopheochromocytoma
- Healthy Volunteers
- (and 2 more...)
|
|
Observational
|
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Other
|
- Sucessful completion of the Clinical Fellowship in autonomic disorders
- Clinical samples and data from evaluation of patients with known or suspected autonomic disorders
|
300 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT02154009 |
140122
14-N-0122 |
|
May 31, 2014 |
April 30, 2019 |
April 30, 2019 |
June 3, 2014 |
October 23, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 35 |
NCT02361944 |
Recruiting |
Risk of Oxygen During Cardiac Surgery Trial |
|
|
Interventional
|
Not Applicable |
- Vanderbilt University
- National Institute of General Medical Sciences (NIGMS)
- Vanderbilt University Medical Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- oxidative damage is the primary outcome of aim 2 (mechanism of organ injury)
- acute kidney injury is the primary outcome of aim 1 (organ injury)
- vascular reactivity / endothelial function
- (and 13 more...)
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT02361944 |
131128
R01GM112871 |
ROCS |
April 2016 |
June 2019 |
December 2020 |
February 12, 2015 |
October 8, 2018 |
|
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
|
| 36 |
NCT03490162 |
Recruiting |
Safety and Pharmacokinetics Study of DM1157 to Treat Malaria |
|
- Drug: DM1157
- Other: Placebo
|
Interventional
|
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Changes in blood pressure in 150 mg Multiple Ascending Dose
- Changes in blood pressure in 150 mg Single Ascending Dose
- Changes in blood pressure in 27 mg Single Ascending Dose
- (and 201 more...)
|
104 |
All |
18 Years to 45 Years (Adult) |
NCT03490162 |
16-0088
HHSN272201500006I |
|
July 17, 2018 |
June 4, 2019 |
June 4, 2019 |
April 6, 2018 |
September 3, 2018 |
|
- Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit
Durham, North Carolina, United States
|
|
| 37 |
NCT02740699 |
Recruiting |
CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction |
|
- Drug: Rosuvastatin
- Drug: Atorvastatin
|
Interventional
|
Phase 4 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To prospectively compare the change in coronary artery plaque burden determined by CCTA in asymptomatic individuals with moderate CVD risk treated either a) according to 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athe...
|
190 |
All |
45 Years to 75 Years (Adult, Older Adult) |
NCT02740699 |
160089
16-H-0089 |
|
April 14, 2016 |
December 15, 2020 |
December 15, 2020 |
April 15, 2016 |
November 5, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 38 |
NCT03589729 |
Recruiting |
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers |
- Acute Myeloid Leukemia
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells
- (and 4 more...)
|
- Drug: Cladribine
- Drug: Cytarabine
- Drug: Dexrazoxane Hydrochloride
- (and 2 more...)
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Percentage of patients experiencing a decrease in left ventricular ejection fraction (LVEF)
- Incidence of cardiac symptoms
- Assessment of change in troponin I and high-sensitivity troponin T
- (and 7 more...)
|
100 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT03589729 |
2017-0937
NCI-2018-01108
P30CA016672 |
|
September 19, 2018 |
December 31, 2020 |
December 31, 2020 |
July 18, 2018 |
November 8, 2018 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 39 |
NCT03326596 |
Recruiting |
Prevention of Postpartum Hemorrhage With TXA |
|
- Drug: Tranexamic Acid 1000 mg/10ml normal saline infusion
|
Interventional
|
Phase 4 |
- United States Naval Medical Center, San Diego
|
U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Incidence of postpartum hemorrhage
- Postpartum blood loss
- Percent decrease in hematocrit
- (and 27 more...)
|
1000 |
Female |
18 Years to 54 Years (Adult) |
NCT03326596 |
NMCSD.2017.0034 |
TXA |
April 20, 2018 |
June 2019 |
September 2019 |
October 31, 2017 |
October 12, 2018 |
|
- Navy Medical Center
San Diego, California, United States
|
|
| 40 |
NCT03524664 |
Recruiting |
A Study of Parent and Child Emotions in Fetal Alcohol Spectrum Disorder (FASD) |
- Fetal Alcohol Spectrum Disorders
|
- Behavioral: Tuning In to kids intervention
|
Interventional
|
Not Applicable |
- University of Rochester
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- mean change in parent awareness of own emotion score for sadness
- mean change in parent acceptance of own expression score for sadness
- mean change in parent regulation of own emotions score for sadness
- (and 18 more...)
|
160 |
All |
4 Years to 12 Years (Child) |
NCT03524664 |
RSRB69545 |
|
August 13, 2018 |
February 28, 2021 |
February 28, 2021 |
May 15, 2018 |
August 29, 2018 |
|
- Mt. Hope Family Center
Rochester, New York, United States
|
|
| 41 |
NCT03621085 |
Recruiting |
Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine |
|
- Drug: Ketamine Hydrochloride
- Other: Placebo
|
Interventional
|
Phase 4 |
- University of Texas Southwestern Medical Center
- United States Department of Defense
|
Other / U.S. Fed |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Tolerance to simulated hemorrhage
- Pain Assessment - Algometer
|
30 |
All |
18 Years to 45 Years (Adult) |
NCT03621085 |
STU 092017-068 |
|
June 1, 2018 |
September 1, 2019 |
May 31, 2021 |
August 8, 2018 |
August 8, 2018 |
|
- Texas Health Presbyterian Hospital Dallas
Dallas, Texas, United States
|
|
| 42 |
NCT02345356 |
Recruiting |
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics |
- Atrial Fibrillation
- Deep Vein Thrombosis
- Cardiac Valvular Insufficiency
- (and 2 more...)
|
- Genetic: Genotype-guided
- Other: Standard-of-Care
|
Observational
|
|
- University of Puerto Rico
- National Institute on Minority Health and Health Disparities (NIMHD)
- Genomas, Inc
|
Other / NIH / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- time spent within therapeutic range
- number of warfarin dose adjustments
- time to stable anticoagulation
- events-free time
|
300 |
All |
21 Years to 90 Years (Adult, Older Adult) |
NCT02345356 |
A4070215
8G12MD007600 |
|
January 2016 |
July 2019 |
July 2019 |
January 26, 2015 |
January 23, 2018 |
|
- Miami VA Healthcare System
Miami, Florida, United States - UPR University Hospital at Carolina
Carolina, Puerto Rico - UDH University Hospital at Centro Medico
San Juan, Puerto Rico
|
|
| 43 |
NCT02439645 |
Recruiting |
A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes |
- Long qt Syndrome
- Torsade de Pointes
|
|
Observational
|
|
- Massachusetts General Hospital
- US Department of Veterans Affairs
- Beth Israel Deaconess Medical Center
- (and 4 more...)
|
Other / U.S. Fed |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Torsade de pointes arrhythmia events
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT02439645 |
2008A055317 |
BA-TdP |
October 2013 |
October 2025 |
October 2025 |
May 12, 2015 |
August 28, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Boston University Medical Center
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - West Roxbury VA Medical Center
West Roxbury, Massachusetts, United States
|
|
| 44 |
NCT03336710 |
Recruiting |
Perspective on Thoughts and Feelings as a Predictor of Psychological Well-being in Daily Life, in a Community Sample |
|
|
Observational
|
|
- State University of New York at Buffalo
- National Center for Complementary and Integrative Health (NCCIH)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Momentary psychological distress
- Momentary eudaimonic well-being
- Momentary hedonic well-being (state positive and negative affect)
- (and 14 more...)
|
368 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03336710 |
1R21AT009470-01
R21AT009470 |
|
July 6, 2017 |
February 28, 2019 |
February 28, 2019 |
November 8, 2017 |
November 8, 2017 |
|
- University at Buffalo, Department of psychology
Buffalo, New York, United States
|
|
| 45 |
NCT02847689 |
Recruiting |
Listening to Mom in the NICU: Neural, Clinical and Language Outcomes |
|
- Behavioral: Language Treatment
- Behavioral: Control Treatment
|
Interventional
|
Phase 1 |
- Stanford University
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- White matter mean diffusivity
- Length of hospital stay
- Average daily weight gain
- (and 2 more...)
|
42 |
All |
24 Weeks to 31 Weeks (Child) |
NCT02847689 |
32638
1K99HD084749-01A1 |
|
July 2016 |
March 2019 |
July 2019 |
July 28, 2016 |
September 6, 2018 |
|
- Stanford University - Lucile Packard Children's Hospital
Palo Alto, California, United States
|
|
| 46 |
NCT02731079 |
Recruiting |
Sleeve Gastrectomy Outcomes With Different Stapling Devices |
|
- Device: Covidien iDrive
- Device: Ethicon Echilon
|
Interventional
|
Not Applicable |
- William Beaumont Army Medical Center
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Time to create sleeve
- Percent of staple firings with technical difficulties
- Time to load staple cartridges
- (and 5 more...)
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT02731079 |
WB16-08 |
|
January 22, 2018 |
March 2020 |
March 2021 |
April 7, 2016 |
November 6, 2018 |
|
- William Beaumont Army Medical Center
El Paso, Texas, United States
|
|
| 47 |
NCT03388294 |
Recruiting |
Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders |
- Autism Spectrum Disorder
- Neurodevelopmental Disorders
|
- Behavioral: Parents and Infants Engaged
|
Interventional
|
Not Applicable |
- University of North Carolina, Chapel Hill
- University of Southern California
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Parent Child Engagement Coding from pretest to posttest 1
- Change in Parent Child Engagement Coding from pretest to posttest 2
- Change in Mullen Scales of Early Learning Receptive Language T-Scores from pretest to posttest 2
- (and 16 more...)
|
44 |
All |
11 Months to 16 Months (Child) |
NCT03388294 |
17-0292
1R21HD091547-01 |
PIE |
March 8, 2018 |
August 15, 2019 |
July 15, 2022 |
January 2, 2018 |
March 15, 2018 |
|
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
|
|
| 48 |
NCT03282981 |
Recruiting |
Beta Adrenergic Antagonist for the Healing of Chronic DFU |
- Chronic Diabetic Foot Ulcers
- Diabetic Neuropathic Ulcers
- Non Healing Wound
|
- Drug: Timolol
- Drug: Non biologically active gel
|
Interventional
|
Phase 3 |
- VA Office of Research and Development
- VA Northern California Health Care System
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to complete wound closure, as assessed over a 12 week period
- Measurement of timolol serum during the treatment phase
- The time to wound closure between the two groups
|
138 |
All |
18 Years and older (Adult, Older Adult) |
NCT03282981 |
SURG-004-16F
17-08-00792 |
BAART-DFU |
June 14, 2018 |
August 1, 2022 |
December 31, 2022 |
September 14, 2017 |
June 19, 2018 |
|
- VA Northern California Health Care System, Mather, CA
Sacramento, California, United States
|
|
| 49 |
NCT03418961 |
Recruiting |
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer |
- Cardiotoxicity
- HER2/Neu Positive
- Metastatic Malignant Neoplasm in the Brain
- (and 2 more...)
|
- Drug: Carvedilol
- Other: Laboratory Biomarker Analysis
- Other: Patient Observation
|
Interventional
|
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Time to the first identification of cardiac dysfunction
- Incidence of adverse events associated with beta blocker treatment
- Rate of first interruption of trastuzumab
- (and 3 more...)
|
817 |
All |
18 Years and older (Adult, Older Adult) |
NCT03418961 |
S1501
NCI-2016-01047
SWOG-S1501
UG1CA189974 |
|
September 15, 2017 |
February 1, 2023 |
February 1, 2023 |
February 1, 2018 |
August 31, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 520 more...)
|
|
| 50 |
NCT02951130 |
Recruiting |
Milrinone in Congenital Diaphragmatic Hernia |
- Congenital Diaphragmatic Hernia
- Persistent Pulmonary Hypertension of the Newborn
- Hypoxemic Respiratory Failure
- Pulmonary Hypoplasia
|
- Drug: Milrinone
- Drug: Placebo (5% Dextrose)
|
Interventional
|
Phase 2 |
- NICHD Neonatal Research Network
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Oxygenation Response
- Oxygenation Response at 48 and 72 h
- Changes in estimated systolic pulmonary arterial pressure on echocardiogram
- (and 11 more...)
|
66 |
All |
up to 168 Hours (Child) |
NCT02951130 |
NICHD-NRN-0057
UG1HD034216
UG1HD027904
UG1HD021364
UG1HD027853
UG1HD040689
UG1HD040492
UG1HD027851
UG1HD087229
UG1HD053109
UG1HD068278
UG1HD068244
UG1HD068263
UG1HD027880
UG1HD053089
UG1HD087226
U10HD036790 |
|
August 22, 2017 |
February 2020 |
February 2021 |
November 1, 2016 |
November 1, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Stanford University
Palo Alto, California, United States - Emory University
Atlanta, Georgia, United States - (and 13 more...)
|
|
| 51 |
NCT03467217 |
Recruiting |
Losartan for the Treatment of Pediatric NAFLD |
- NAFLD - Nonalcoholic Fatty Liver Disease
|
- Drug: Losartan potassium
- Drug: Placebo losartan capsule
|
Interventional
|
Phase 2 |
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Johns Hopkins University
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in serum alanine aminotransferase (ALT) from baseline.
- Relative change in serum alanine aminotransferase (ALT) compared to baseline ALT
- Proportion of patients achieving normalization of ALT
- (and 11 more...)
|
110 |
All |
8 Years to 17 Years (Child) |
NCT03467217 |
9 STOP-NAFLD
U01DK061730 |
STOP-NAFLD |
October 2, 2018 |
April 16, 2019 |
August 30, 2019 |
March 15, 2018 |
November 1, 2018 |
|
- University of California, San Diego
San Diego, California, United States - University of California, San Francisco
San Francisco, California, United States - Emory University
Atlanta, Georgia, United States - (and 7 more...)
|
|
| 52 |
NCT02353312 |
Recruiting |
Rhode Island Diastolic Dysfunction - Heart Failure |
- Heart Failure
- Cardiovascular Disease
|
|
Interventional
|
Not Applicable |
- Providence VA Medical Center
- BioMarin Pharmaceutical
- Lifespan
|
U.S. Fed / Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in VO2 consumption
- Change from baseline in echocardiographic parameters of diastolic dysfunction
- Change from baseline in Quality of life measured by Kansas City Cardiomyopathy Questionnaire
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT02353312 |
2014-051 |
RIDD-HF |
March 2015 |
December 2018 |
December 2018 |
February 2, 2015 |
April 11, 2018 |
|
- Providence VAMC
Providence, Rhode Island, United States
|
|
| 53 |
NCT03371823 |
Recruiting |
Vascular Dysfunction in Hypertensive Postmenopausal Women |
- Cardiovascular Diseases
- Hypertension
|
- Other: Normotensive
- Drug: Hypertensives
|
Interventional
|
Phase 4 |
- University of Delaware
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- ET-1 mediated constriction
- Endothelin Receptor A and B expression
|
50 |
Female |
50 Years to 70 Years (Adult, Older Adult) |
NCT03371823 |
1009297 |
|
September 1, 2017 |
February 28, 2019 |
December 31, 2019 |
December 13, 2017 |
October 3, 2018 |
|
- University of Delaware
Newark, Delaware, United States
|
|
| 54 |
NCT02373241 |
Recruiting |
Preventing Sickle Cell Kidney Disease |
- Anemia, Sickle Cell
- Sickle Cell Disease
- Kidney Disease
- (and 2 more...)
|
|
Interventional
|
Phase 2 |
- University of Alabama at Birmingham
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility as measured by the number of patients that accept enrollment, remain adherent to losartan, and remain adherent to study procedures.
- Feasibility as measured by number of patients with adverse events to losartan.
- To prospectively evaluate the incidence of hypertension (clinic and ambulatory) in patients with SCD and number of patients with abnormal blood pressure biomarkers.
- Feasibility as measured by the number of patients with improvement in nocturnal blood pressure while receiving losartan.
|
40 |
All |
5 Years to 25 Years (Child, Adult) |
NCT02373241 |
F141107009
1K23HL127100-01 |
|
April 2015 |
April 2020 |
April 2020 |
February 26, 2015 |
May 1, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 55 |
NCT02784821 |
Recruiting |
Antibiotic "Dysbiosis" in Preterm Infants |
- Enterocolitis, Necrotizing
- Bacteremia
- Bronchopulmonary Dysplasia
- (and 5 more...)
|
- Drug: Antibiotic
- Other: Gastric fluid
- Other: Breast milk
- (and 3 more...)
|
Interventional
|
Phase 2 |
- University of Florida
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Society for Pediatric Dermatology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rates of necrotizing enterocolitis(NEC)
- Rates of bacteremia
- Microbiota 16s ribosomal ribonucleic acid (rRNA) metagenomic sequencing
- (and 13 more...)
|
420 |
All |
23 Weeks to 33 Weeks (Child) |
NCT02784821 |
IRB201501045-N
R21HD088005 |
|
January 2017 |
September 2019 |
December 2019 |
May 27, 2016 |
September 12, 2018 |
|
- University of Florida
Gainesville, Florida, United States
|
|
| 56 |
NCT03115463 |
Recruiting |
Saturation Targets and Resuscitation in Preterm Trial |
|
- Other: Titration of oxygen during neonatal resuscitation
|
Interventional
|
Not Applicable |
- University of Texas Southwestern Medical Center
- American Academy of Pediatrics
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Oxidative Balance Ratio from Baseline
- Reduction in Isoprostane,Isofluran, 8-OHdG and protein carbonyls
- • Reduction in oxygen load in the delivery room
- (and 9 more...)
|
75 |
All |
Child, Adult, Older Adult |
NCT03115463 |
STU-062014-010
1K23HD083511-01A1 |
STARTPreterm |
September 20, 2017 |
June 2019 |
June 2020 |
April 14, 2017 |
August 24, 2018 |
|
- Parkland Hospital
Dallas, Texas, United States
|
|
| 57 |
NCT03419260 |
Recruiting |
Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children |
|
- Other: Clinically indicated EEG monitoring.
|
Observational
|
|
- Children's Hospital of Philadelphia
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Electrographic Seizure Occurrence
- Safety - Mortality
- Safety - Occurrence of Cardiopulmonary adverse effects
- (and 2 more...)
|
900 |
All |
1 Month to 18 Years (Child, Adult) |
NCT03419260 |
17-013808
K02NS096058 |
|
March 13, 2017 |
March 1, 2020 |
May 1, 2020 |
February 1, 2018 |
February 1, 2018 |
|
- Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 58 |
NCT03152864 |
Not yet recruiting |
Stabilizing Behavioral Rhythms to Improve Mental Health |
- Depressive Symptoms
- Anxiety Symptoms
- Sleep Symptoms
|
|
Interventional
|
Not Applicable |
- HealthRhythms, Inc.
- National Institute of Mental Health (NIMH)
- University of Utah
|
Industry / NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- PROMIS Depression
- PROMIS Anxiety
- PROMIS Sleep
|
128 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03152864 |
1R44MH113520
R44MH113520 |
SRMH |
March 1, 2018 |
March 31, 2019 |
March 31, 2019 |
May 15, 2017 |
August 28, 2017 |
|
|
|
| 59 |
NCT02587351 |
Recruiting |
Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: Metoprolol succinate
- Other: Placebo
|
Interventional
|
Phase 3 |
- University of Minnesota - Clinical and Translational Science Institute
- United States Department of Defense
- University of Alabama at Birmingham
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- First occurrence of an acute COPD exacerbation
- Number of acute exacerbations of COPD
- Number of Emergency Department visits resulting from acute exacerbations of COPD
- (and 15 more...)
|
1028 |
All |
40 Years to 84 Years (Adult, Older Adult) |
NCT02587351 |
PR140170 |
|
May 2016 |
May 2020 |
May 2020 |
October 27, 2015 |
May 31, 2018 |
|
- Birmingham, Alabama VA Medical
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - University of California, San Francisco-Fresno
Fresno, California, United States - (and 24 more...)
|
|
| 60 |
NCT02263729 |
Recruiting |
Phase 1/2 Prospective Double-blind, Placebo-controlled Randomized Clinical Trial Using Losartan to Treat Grade II and III Hamstring Strains |
|
- Drug: Losartan
- Drug: placebo
|
Interventional
|
Phase 1
Phase 2 |
- James J. Irrgang
- Brooke Army Medical Center
- Wake Forest University
- University of Pittsburgh
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reported effects of losartan for hamstring injury for safety and tolerability
- Recovery of hamstring muscle function and structure
- Return to prior level of function
- Recurrence of injury
|
10 |
All |
18 Years to 35 Years (Adult) |
NCT02263729 |
PRO14050083
W81XWH-13-2-0052 |
|
July 2016 |
December 2018 |
December 31, 2018 |
October 13, 2014 |
January 17, 2018 |
|
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
|
| 61 |
NCT03067311 |
Recruiting |
Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy |
- Schizophreniform Disorders
|
- Behavioral: I-CAT
- Behavioral: Treatment as Usual
|
Interventional
|
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline Quality of Life Scale (QLS; Bilker et al., 2003)
- Change in salivary cortisol
- Change in urinary cortisol
- (and 18 more...)
|
40 |
All |
15 Years to 35 Years (Child, Adult) |
NCT03067311 |
16-1173
4R33MH100250-03 |
I-CAT |
October 3, 2016 |
October 2019 |
October 2019 |
March 1, 2017 |
May 25, 2018 |
|
- UNC OASIS Carrboro
Carrboro, North Carolina, United States - UNC STEP
Carrboro, North Carolina, United States - UNC Oasis Wake
Raleigh, North Carolina, United States - UNC Wake STEP
Raleigh, North Carolina, United States
|
|
| 62 |
NCT02830126 |
Recruiting |
Anesthesiology Control Tower |
- Health Information Technology
|
- Other: Anesthesiology Control Tower Feedback
|
Interventional
|
Not Applicable |
- Washington University School of Medicine
- Agency for Healthcare Research and Quality (AHRQ)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Other
|
- Compliance with recommendations for intraoperative temperature management
- Compliance with recommendations for intraoperative blood glucose management
- Assess the usability of the Anesthesiology Control Tower (ACT) for an operating suite
- (and 15 more...)
|
12000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02830126 |
201603038
1R21HS024581-01A1 |
ACTFAST |
November 2016 |
December 2018 |
December 2019 |
July 12, 2016 |
May 10, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 63 |
NCT02019706 |
Recruiting |
Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome |
|
- Drug: F-DOPA PET Scan
- Drug: Mifepristone
- Drug: Ga-DOTATATE
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Which imaging technique (TATA PET/CT, Ga-DOTATATE PET/CT, OCT, CT and MRI) has the best sensitivity?
|
80 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT02019706 |
140028
14-CH-0028 |
|
November 26, 2013 |
August 15, 2019 |
August 15, 2019 |
December 24, 2013 |
October 2, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 64 |
NCT03109288 |
Recruiting |
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) |
|
- Drug: Pioglitazone
- Drug: Montelukast
- Drug: Losartan
- Drug: Hydroxychloroquine
|
Interventional
|
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary outcome will be the change in the CombiWISE progression rate at the end of monotherapy plus combination therapy period in comparison to projected baseline disability progression.
- Safety and tolerability of individual drugs and their combinations
- Change in the rate of ventricular atrophy between baseline, monotherapy and combination therapy periods, measured by linear regression slopes greater than or equal to 3 time-points for each period
- (and 2 more...)
|
250 |
All |
18 Years and older (Adult, Older Adult) |
NCT03109288 |
170083
17-I-0083 |
|
August 11, 2017 |
June 1, 2030 |
June 1, 2030 |
April 12, 2017 |
November 2, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 65 |
NCT03464396 |
Recruiting |
Prematurity-Related Ventilatory Control |
- Respiratory Control in Premature Infants
|
- Other: Bedside Physiology study
- Other: Carotid Body Function Test
- Other: Room Air Challenge
- (and 5 more...)
|
Observational
|
|
- Washington University School of Medicine
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Respiratory phenotype based on physiologic testing
|
375 |
All |
up to 7 Days (Child) |
NCT03464396 |
201611138
5U01HL133700-02 |
PreVent |
May 14, 2018 |
June 1, 2021 |
June 30, 2021 |
March 14, 2018 |
May 16, 2018 |
|
- Washington University
Saint Louis, Missouri, United States
|
|
| 66 |
NCT00001849 |
Recruiting |
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome |
|
- Drug: Pentetreotide
- Drug: 18-F-fluorodeoxyglucose
- Drug: (18F)-L-3,4-dihydroxyophenylalanine (18F-DOPA)
|
Interventional
|
Phase 1
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Sensitivity, specificity and diagnostic accuracy of imaging modalities for the detection of ACTH-secreting non-pituitary tumor
|
202 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT00001849 |
990055
99-CH-0055 |
|
February 26, 1999 |
December 31, 2019 |
December 31, 2019 |
November 4, 1999 |
July 16, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 67 |
NCT03616262 |
Recruiting |
"Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome" |
- Complex Regional Pain Syndrome
|
- Drug: Botox + Lidocaine
- Drug: Lidocaine alone
|
Interventional
|
Early Phase 1 |
- VA Connecticut Healthcare System
- Allergan
|
U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Reduction in the VAS score will be the primary outcome measure.
- Quality of Life as a measure of function with pain.
- Disability
- (and 5 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03616262 |
VACHS |
|
July 2016 |
December 2019 |
December 2019 |
August 6, 2018 |
August 6, 2018 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 68 |
NCT03537534 |
Recruiting |
Intraurethral Lidocaine After Endourology Procedures |
|
- Drug: Lidocaine Jet Injector
- Drug: Placebos
|
Interventional
|
Phase 3 |
- San Antonio Uniformed Services Health Education Consortium
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Subjective patient symptom score
- Patient complications
|
100 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03537534 |
C.2018.055d |
|
April 15, 2018 |
February 2019 |
May 2019 |
May 25, 2018 |
May 25, 2018 |
|
- BAMC
Fort Sam Houston, Texas, United States
|
|
| 69 |
NCT02496676 |
Recruiting |
Magnesium Supplementation in People With XMEN Syndrome |
- X-linked Immunodeficiency With Magnesium Defect
- Epstein-Barr Virus (EBV) Infection and Neoplasia
|
- Drug: Magnesium L-threonate
- Drug: Placebo
- Drug: Magnesium Sulfate (MgSO)
|
Interventional
|
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To investigate the efficacy of magnesium supplementation in patients with XMEN syndrome by comparing the absolute number ofEBV-infected B cells after 12 weeks of oral magnesium and after 12 weeks of placebo.
- To assess the safety and tolerability of MgSO4 IV infusion and oral magnesium L-threonate
- To evaluate the effects of magnesium supplementation on intracellular free magnesium (Mg2+) concentrations in peripheral blood T cell lymphocytes
- Contingent upon patient participation in Part II, to compare the effects of 2 different supplementation regimens (oral magnesium L-threonate with and without initial infusion of IV MgSO4) on EBV viral load and number (or percent) of EBV-infected...
|
30 |
Male |
6 Years and older (Child, Adult, Older Adult) |
NCT02496676 |
150161
15-I-0161 |
|
July 9, 2015 |
June 1, 2020 |
December 1, 2020 |
July 14, 2015 |
August 9, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 70 |
NCT02293096 |
Recruiting |
Pharmacogenetic Prediction of Metoprolol Effectiveness |
|
- Drug: metoprolol succinate
- Genetic: Genotyping
- Procedure: CYP2D6 Phenotyping
|
Interventional
|
Not Applicable |
- University of Colorado, Denver
- National Institute of General Medical Sciences (NIGMS)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Blood pressure decline
- Heart rate decline
- Adverse Drug Events
|
500 |
All |
30 Years to 80 Years (Adult, Older Adult) |
NCT02293096 |
13-3174
1K23GM110516-01 |
|
September 2014 |
September 2019 |
March 2020 |
November 18, 2014 |
March 30, 2018 |
|
- University of Colorado Denver; Emergency Department
Aurora, Colorado, United States
|
|
| 71 |
NCT02823665 |
Recruiting |
The Effects of Bariatric Surgeries on Glucose Metabolism |
- Post Bariatric Surgery
- Gastric Bypass
- Sleeve Gastrectomy
- Hypoglycemia After Gastric Bypass
|
- Drug: Exendin-(9-39)
- Drug: Atropine
|
Interventional
|
Early Phase 1 |
- The University of Texas Health Science Center at San Antonio
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Other
|
- Insulin levels measured after nutrient ingestion
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02823665 |
20180070H
1R01DK105379-01 |
|
July 2015 |
July 2022 |
July 2022 |
July 6, 2016 |
May 18, 2018 |
|
- South Texas Veterans Health Care System
San Antonio, Texas, United States
|
|
| 72 |
NCT03505736 |
Recruiting |
Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer |
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage IB Breast Cancer AJCC v8
- (and 18 more...)
|
- Biological: Adenosine
- Procedure: Magnetic Resonance Imaging
- Drug: Regadenoson
- Procedure: Stress Management Therapy
|
Observational
|
|
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Myocardial perfusion reserve index (MPRI)
- Myocardial rest myocardial fibrosis burden (T1) and left ventricular ejection fraction (LVEF)
- Change in MPRI measures
- (and 2 more...)
|
21 |
Female |
up to 50 Years (Child, Adult) |
NCT03505736 |
IRB00049171
NCI-2018-00588
CCCWFU 98118
P30CA012197 |
|
June 21, 2018 |
May 2019 |
May 2020 |
April 23, 2018 |
June 29, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 73 |
NCT03029091 |
Recruiting |
An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) |
|
|
Interventional
|
Phase 2 |
- Children's Hospital Medical Center, Cincinnati
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Allergy and Infectious Diseases (NIAID)
- (and 2 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Peak Esophageal Eosinophil Count
- Change in TGF-beta levels
|
15 |
All |
5 Years to 25 Years (Child, Adult) |
NCT03029091 |
2015-9021 |
|
January 19, 2017 |
November 2018 |
August 2019 |
January 24, 2017 |
September 21, 2018 |
|
- University of California, San Diego
La Jolla, California, United States - Northwestern University
Chicago, Illinois, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
|
| 74 |
NCT03072589 |
Recruiting |
Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation |
|
- Drug: Regadenoson infusion
|
Interventional
|
Phase 1 |
- Christine Lau, MD
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Virginia
|
Other / NIH |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patient tolerability of assigned dose and duration
- Activation of iNKT cells
- Clinical Pulmonary Graft Dysfunction (PGD) score
- Inflammatory Cytokines in blood and bronchioalveolar lavage
|
21 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03072589 |
UVA-LAU-01
1R01HL128492-01A1 |
|
November 30, 2017 |
August 1, 2020 |
August 1, 2021 |
March 7, 2017 |
February 8, 2018 |
|
- University of Virginia
Charlottesville, Virginia, United States
|
|
| 75 |
NCT03064295 |
Recruiting |
Whole-Heart Myocardial Blood Flow Quantification Using MRI |
- Coronary Artery Disease
- Coronary Microvascular Disease
|
- Device: Myocardial Perfusion Cardiac MRI.
- Drug: Contrast
- Drug: Pharmacologic Stress Agent
|
Observational
|
|
- Cedars-Sinai Medical Center
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
- CAD findings by MRI
- CMD findings by MRI
|
160 |
All |
18 Years and older (Adult, Older Adult) |
NCT03064295 |
42972
1R01HL124649 |
|
March 1, 2018 |
January 1, 2025 |
January 1, 2025 |
February 27, 2017 |
March 13, 2018 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States
|
|
| 76 |
NCT03588754 |
Not yet recruiting |
Does Propanolol, a Beta Blocker, Attenuate Stress-Induced Drinking? |
|
- Drug: Propanolol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Yale University
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
20 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03588754 |
2000022090
R01AA022285 |
|
September 15, 2018 |
July 31, 2019 |
July 31, 2019 |
July 17, 2018 |
September 11, 2018 |
|
|
|
| 77 |
NCT03526874 |
Not yet recruiting |
Occipital Blocks for Acute Migraine |
- Chronic Migraine, Headache
- Episodic Migraine
|
- Drug: Lidocaine 4% Topical Application Cream [LMX 4]
- Drug: Lidocaine Hydrochloride 2 mg/mL Injectable Solution
- Drug: Normal Saline
|
Interventional
|
Phase 3 |
- Children's Hospital of Philadelphia
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change in Pain Intensity Scores
- Change from Baseline Disability
- Percentage of Subjects with Pain Freedom
- (and 3 more...)
|
58 |
All |
7 Years to 17 Years (Child) |
NCT03526874 |
18-014939 |
|
November 2018 |
November 2021 |
December 2021 |
May 16, 2018 |
October 24, 2018 |
|
- Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 78 |
NCT02509546 |
Recruiting |
8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Recurrent Adult Acute Myeloid Leukemia
- Relapsed Adult Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Acute Myeloid Leukemia Arising From Previous Myeloproliferative Disorder
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: 8-chloro-adenosine
|
Interventional
|
Phase 1
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete remission rate (CR + CRi), calculated as the percent of evaluable patients that have confirmed CR or CRi (Phase II)
- Incidence of toxicity, graded according to the NCI CTCAE version 4.03
- Maximum tolerated dose of 8-chloro-adenosine, defined as the highest dose at which =< 1/6 patients in a cohort experience a dose limiting toxicity (DLT) (Phase I)
- (and 4 more...)
|
43 |
All |
18 Years and older (Adult, Older Adult) |
NCT02509546 |
14269
NCI-2015-00871 |
|
September 2, 2015 |
February 2019 |
February 2019 |
July 28, 2015 |
June 19, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States
|
|
| 79 |
NCT03417388 |
Recruiting |
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD |
|
- Drug: High dose potent statin
- Drug: ACE-I (lisinopril) or ARB (losartan)
- Drug: Aspirin
- (and 2 more...)
|
Interventional
|
Phase 4 |
- University of Florida
- United States Department of Defense
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- All Cause Death incidents reported between the two groups
- Non-fatal myocardial infarction (MI) incidents reported between the two groups
- Stroke/TIA incidents reported between the two groups
- (and 2 more...)
|
550 |
Female |
18 Years to 100 Years (Adult, Older Adult) |
NCT03417388 |
IRB201701142 -A
W81XWH-17-2-0030 |
WARRIOR |
February 9, 2018 |
December 30, 2021 |
December 30, 2022 |
January 31, 2018 |
November 15, 2018 |
|
- Cedars-Sinai Heart Institute
Los Angeles, California, United States - LA BioMedical
Torrance, California, United States - Family Medicine at Eastside Community Practice
Gainesville, Florida, United States - (and 20 more...)
|
|
| 80 |
NCT03384836 |
Recruiting |
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery |
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
|
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
- Drug: Propranolol Hydrochloride
|
Interventional
|
Phase 1
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose limiting toxicities (DLT) defined as any grade 3 or higher hematological or non-hematological toxicity that is probably or definitely related to treatment according to Common Terminology Criteria for Adverse Events version 4.03 (Phase Ib)
- Overall response rate (ORR) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) version 1.1 (Phase II)
- Overall survival (OS) (Phase II)
- (and 2 more...)
|
47 |
All |
18 Years and older (Adult, Older Adult) |
NCT03384836 |
I 53217
NCI-2017-02210
P30CA016056 |
|
January 31, 2018 |
October 11, 2019 |
October 11, 2020 |
December 27, 2017 |
June 6, 2018 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 81 |
NCT03251326 |
Recruiting |
Nabilone in Cannabis Users With PTSD |
- Cannabis
- Post Traumatic Stress Disorder
|
- Drug: Nabilone
- Drug: Cannabis
- Drug: Propranolol
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- New York State Psychiatric Institute
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
|
14 |
All |
21 Years to 45 Years (Adult) |
NCT03251326 |
6971
U54DA037842 |
|
October 2015 |
August 2019 |
August 2019 |
August 16, 2017 |
August 16, 2018 |
|
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 82 |
NCT03152786 |
Recruiting |
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery |
|
- Other: Laboratory Biomarker Analysis
- Drug: Propranolol Hydrochloride
- Other: Questionnaire Administration
- Other: Survey Administration
|
Interventional
|
Phase 2 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CREB phosphorylation
- BAD phosphorylation
- Distress score
- (and 4 more...)
|
50 |
Male |
19 Years and older (Adult, Older Adult) |
NCT03152786 |
IRB00043227
NCI-2017-00788
CCCWFU 85716
P30CA012197 |
|
February 12, 2018 |
February 2019 |
February 2019 |
May 15, 2017 |
July 4, 2018 |
|
- Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, United States
|
|
| 83 |
NCT03013933 |
Recruiting |
Brentuximab Vedotin, Cyclosporine, and Verapamil in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- CD30-Positive Neoplastic Cells Present
|
- Drug: Brentuximab Vedotin
- Drug: Cyclosporine
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional
|
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity assessed by National Cancer Institute (NCI) CTCAE version 4.03
- Complete response rate assessed by Cheson 2014 criteria
- Duration of complete response
- (and 5 more...)
|
39 |
All |
15 Years and older (Child, Adult, Older Adult) |
NCT03013933 |
16414
NCI-2016-02062 |
|
May 3, 2017 |
March 2019 |
March 2019 |
January 9, 2017 |
October 24, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States
|
|
| 84 |
NCT02871349 |
Recruiting |
Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response |
|
- Drug: Propranolol
- Drug: Placebo
- Device: Magnetic Resonance Imaging (MRI)
|
Interventional
|
Early Phase 1 |
- University of Missouri-Columbia
- United States Department of Defense
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in General Social Outcomes Measure (GSOM) Assessment
- Change in Social Responsiveness Scale (SRS-2)
- Change in score on Anagrams test
- (and 7 more...)
|
96 |
All |
7 Years to 24 Years (Child, Adult) |
NCT02871349 |
2005213 |
|
August 2016 |
September 2020 |
September 2020 |
August 18, 2016 |
July 16, 2018 |
|
- Thompson Center for Autism & Neurodevelopmental Disorders
Columbia, Missouri, United States
|
|
| 85 |
NCT02596776 |
Recruiting |
Cold Induced Changes in White Adipose |
- Obese
- Normal Body Weight
- Prediabetes
- Metabolic Syndrome
|
- Procedure: Fat biopsy
- Drug: Propranolol and fat biopsy
- Other: heavy water and fat biopsy
|
Interventional
|
Early Phase 1 |
- Philip Kern
- National Institutes of Health (NIH)
- University of Kentucky
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- WAT changes during repeated exposure to cold temperatures
- WAT changes following Propranolol dosing
- In vivo measurement of adipose lipolysis and triglyceride (TG) turnover
|
90 |
Female |
35 Years to 60 Years (Adult) |
NCT02596776 |
15-0663 |
|
March 2016 |
December 2019 |
December 2019 |
November 4, 2015 |
May 8, 2018 |
|
- University of Kentucky Medical Center Center for Clinical and Translational Science
Lexington, Kentucky, United States
|
|
| 86 |
NCT02390284 |
Recruiting |
Stop Retinal Ganglion Cell Dysfunction Study |
|
- Drug: Latanoprost
- Drug: Bimatoprost
- Drug: Travoprost
- (and 5 more...)
|
Interventional
|
Phase 3 |
- University of Miami
- National Eye Institute (NEI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Retinal Nerve Fiber Layer Thickness change through Optical Coherence Tomography evaluation
- Pattern Electroretinogram Changes
|
500 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02390284 |
20140587
R01EY014957 |
STOP-RGCD |
September 2014 |
July 2019 |
July 2019 |
March 17, 2015 |
December 18, 2017 |
|
- Bascom Palmer Eye Institute - University of Miami
Miami, Florida, United States
|
|
| 87 |
NCT00675714 |
Recruiting |
Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation |
|
- Procedure: Stable Isotope Infusion Study
- Procedure: Collection of blood and tissues
- Procedure: Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI
- (and 9 more...)
|
Interventional
|
Phase 2
Phase 3 |
- The University of Texas Medical Branch, Galveston
- U.S. Department of Education
- National Institutes of Health (NIH)
- National Institute of General Medical Sciences (NIGMS)
|
Other / U.S. Fed / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Outcome assessments will include measures of muscle wasting, weakness, immunosuppression chronic bone loss and decreased growth with increases in metabolic, hemodynamic, inflammatory and scarring responses.
|
1100 |
All |
up to 80 Years (Child, Adult, Older Adult) |
NCT00675714 |
04-157
NIDILRR 90DP0043-03-00
P50GM060338 |
|
January 2004 |
September 2018 |
September 2018 |
May 12, 2008 |
May 31, 2017 |
|
- University of Texas Medical Branch
Galveston, Texas, United States
|
|
| 88 |
NCT03079921 |
Recruiting |
Adrenergic System in Islet Transplantation |
- Type1diabetes
- Hypoglycemia
- Hypoglycemia Unawareness
|
- Drug: Phentolamine
- Drug: Propranolol
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
- University of Pennsylvania
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- C-PEPTIDE suppression during hyperinsulinemia euglycemia.
- GLUCAGON activation during hyperinsulinemia hypoglycemia.
- EPINEPHRINE during hyperinsulinemia hypoglycemia.
- (and 2 more...)
|
45 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03079921 |
826386
2R01DK091331-06 |
Aim 1 Islets |
January 20, 2017 |
December 2019 |
December 2020 |
March 15, 2017 |
August 24, 2018 |
|
- University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism
Philadelphia, Pennsylvania, United States
|
|
| 89 |
NCT03309943 |
Recruiting |
Neurobehavioral Substrates of Proranolol's Effects on Drug Cue Reactivity |
|
- Drug: Propranolol
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Duke University
- National Institutes of Health (NIH)
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- fMRI BOLD Activation
- fMRI Connectivity
- Craving
- Number of puffs taken during ad lib smoking period
|
50 |
All |
18 Years to 55 Years (Adult) |
NCT03309943 |
Pro00083809 |
ProCue |
January 16, 2018 |
August 31, 2019 |
August 31, 2019 |
October 16, 2017 |
October 18, 2018 |
|
- Duke University School of Medicine
Durham, North Carolina, United States
|
|
| 90 |
NCT02620579 |
Recruiting |
Biopsychosocial Influence on Shoulder Pain |
|
- Drug: Propranolol LA (60 mg)
- Drug: Placebo
- Behavioral: Shoulder Anatomy Education
- Behavioral: Pain Processing Education
|
Interventional
|
Phase 2 |
- Duke University
- National Institutes of Health (NIH)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Brief Pain Inventory (BPI) for pain duration
- Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH)
- Brief Pain Inventory (BPI) for peak shoulder pain intensity (highest daily pain intensity rating) recorded during recovery.
- (and 7 more...)
|
448 |
All |
18 Years to 64 Years (Adult) |
NCT02620579 |
Pro00078287
2R01AR055899 |
BISP |
January 2016 |
December 2020 |
December 2020 |
December 3, 2015 |
May 18, 2018 |
|
- University of Florida Clinical and Translational Science Institute
Gainesville, Florida, United States
|
|
| 91 |
NCT01209000 |
Recruiting |
Nephrotic Syndrome Study Network |
- Minimal Change Disease (MCD)
- Membranous Nephropathy
- Glomerulosclerosis, Focal Segmental
|
|
Observational
|
|
- University of Michigan
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- The NephCure Foundation
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Event rate of change in urinary protein excretion and renal function.
- Rate of change in renal function.
- Quality of Life:
- (and 8 more...)
|
1200 |
All |
up to 80 Years (Child, Adult, Older Adult) |
NCT01209000 |
6801
1U54DK083912 |
NEPTUNE |
April 2010 |
June 2019 |
June 30, 2019 |
September 24, 2010 |
October 24, 2018 |
|
- University of Southern California-Children's Hospital
Los Angeles, California, United States - Stanford University School of Medicine
Palo Alto, California, United States - Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
Torrance, California, United States - (and 32 more...)
|
|
| 92 |
NCT03734393 |
Not yet recruiting
New |
HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients |
|
|
Interventional
|
Phase 2 |
- Johns Hopkins University
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to first death or graft failure or serious adverse event (SAE) or HIV breakthrough or opportunistic infection as a composite measure
- Time to Pre-transplant mortality
- Graft Failure as assessed by Time to first occurrence of mortality or re-transplant or return to maintenance dialysis
- (and 37 more...)
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03734393 |
IRB00178771
U01AI138897 |
|
December 15, 2018 |
June 30, 2022 |
June 30, 2022 |
November 8, 2018 |
November 9, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of California, San Diego
San Diego, California, United States - University of California, San Francisco
San Francisco, California, United States - (and 16 more...)
|
|
| 93 |
NCT03334253 |
Recruiting |
Low-Dose Atropine for Treatment of Myopia |
|
- Drug: Atropine
- Other: Placebo Eyedrops
|
Interventional
|
Phase 3 |
- Jaeb Center for Health Research
- Pediatric Eye Disease Investigator Group
- National Eye Institute (NEI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment group comparison of change in spherical equivalent refractive error.
- Treatment group comparison of change from baseline to 30 months in spherical equivalent
|
186 |
All |
5 Years to 12 Years (Child) |
NCT03334253 |
MTS1
2U10EY011751 |
MTS1 |
June 1, 2018 |
May 2022 |
October 2022 |
November 7, 2017 |
November 6, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - The Emory Eye Center Dept of Ophthalmology
Atlanta, Georgia, United States - St Luke's Hospital
Boise, Idaho, United States - (and 7 more...)
|
|
| 94 |
NCT02675244 |
Recruiting |
Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery |
- Mild Tricuspid Regurgitation
- Moderate Tricuspid Regurgitation
- Tricuspid Regurgitation
|
- Procedure: TV Annuloplasty
- Procedure: MVS
|
Interventional
|
Not Applicable |
- Icahn School of Medicine at Mount Sinai
- National Heart, Lung, and Blood Institute (NHLBI)
- Canadian Institutes of Health Research (CIHR)
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Degree of TR Repair
- MACCE
- NYHA Classification
- (and 21 more...)
|
400 |
All |
18 Years and older (Adult, Older Adult) |
NCT02675244 |
GCO 08-1078-0010
2U01HL088942-07 |
|
May 26, 2016 |
December 2019 |
December 2023 |
February 5, 2016 |
October 30, 2018 |
|
- University of Southern California
Los Angeles, California, United States - Stanford University School of Medicine
Stanford, California, United States - Yale University School of Medicine - Yale-New Haven Hospital
New Haven, Connecticut, United States - (and 35 more...)
|
|
| 95 |
NCT03489122 |
Not yet recruiting |
A Randomized Control Trial Treating Depression With Yoga and Coherent Breathing Versus Walking in Veterans |
- Depressive Disorder, Major
- Post Traumatic Stress Disorder
|
- Behavioral: yoga
- Behavioral: walking
|
Interventional
|
Phase 1
Phase 2 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scales Change
- Gamma Amino Butyric Acid (GABA) Change
|
420 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03489122 |
MHBB-001-17S |
|
October 1, 2018 |
March 30, 2023 |
September 30, 2023 |
April 5, 2018 |
September 14, 2018 |
|
- Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA
Bedford, Massachusetts, United States
|
|
| 96 |
NCT02452255 |
Recruiting |
Fenofibrate and Propranolol in Burn Patients |
|
- Drug: Fenofibrate
- Drug: Placebo
- Drug: Propranolol
|
Interventional
|
Phase 2
Phase 3 |
- The University of Texas Medical Branch, Galveston
- National Institute of General Medical Sciences (NIGMS)
- Shriners Hospitals for Children
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Glucose Metabolism
- Hypermetabolism
- Rate pressure product
|
330 |
All |
up to 80 Years (Child, Adult, Older Adult) |
NCT02452255 |
14-0441
NIH RO1GM056687 |
|
November 2015 |
December 2022 |
December 2022 |
May 22, 2015 |
September 11, 2018 |
|
- Shriners Hospitals for Children
Galveston, Texas, United States
|
|
| 97 |
NCT01902810 |
Recruiting |
Protective Effects of Propranolol in Adults |
|
- Drug: Propranolol
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- The University of Texas Medical Branch, Galveston
- United States Department of Defense
- American Burn Association
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Cardiac rate pressure product
- Mortality rates
|
250 |
All |
18 Years and older (Adult, Older Adult) |
NCT01902810 |
12-205 |
|
July 2013 |
June 2019 |
December 2019 |
July 18, 2013 |
September 11, 2018 |
|
- University of Florida
Gainesville, Florida, United States - Loyola University Burn Center
Maywood, Illinois, United States - University of Iowa
Iowa City, Iowa, United States - (and 7 more...)
|
|
| 98 |
NCT02913612 |
Recruiting |
Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) |
|
- Drug: 0.25% Timolol Maleate Gel Forming Solution
- Drug: 0.5% Timolol Maleate Gel Forming Solution
|
Interventional
|
Phase 2 |
- Chiara Melloni
- The EMMES Corporation
- National Institutes of Health (NIH)
- Duke University
|
Other / Industry / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Comparison of partial response of hemangioma volume within the treat arm compared to the untreated controls
- Efficacy Comparison of proportion of infants with partial response or greater change in volume
- Efficacy comparison of proportion of infants with partial response between the two treatment arms
- (and 9 more...)
|
110 |
All |
up to 84 Days (Child) |
NCT02913612 |
Pro00068212 |
TIM01 |
May 5, 2017 |
September 28, 2019 |
September 28, 2019 |
September 26, 2016 |
November 2, 2018 |
|
- Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States - Indiana University Health
Indianapolis, Indiana, United States - Johns Hopkins Medical Center
Baltimore, Maryland, United States - (and 9 more...)
|
|
| 99 |
NCT01555554 |
Recruiting |
Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD) |
- Post-traumatic Stress Disorder
|
- Drug: Propranolol Hydrochloride
- Other: Placebo
|
Interventional
|
Not Applicable |
- University of California, San Francisco
- United States Department of Defense
- Northern California Institute of Research and Education
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- ICU length of stay
- Hospital length of stay
- Postoperative delirium
- (and 14 more...)
|
110 |
All |
40 Years and older (Adult, Older Adult) |
NCT01555554 |
W81XWH-10-2-0078 |
|
May 2012 |
June 2019 |
June 2019 |
March 15, 2012 |
May 17, 2018 |
|
- San Francisco VA Medical Center
San Francisco, California, United States
|
|
| 100 |
NCT03096678 |
Recruiting |
Prognosis of Patients With Compete Left Bundle Branch Block |
- Bundle-Branch Block, Left
- Cardiac Failure
- ICD/Pacemaker Implantation
- Cardiovascular Magnetic Resonance Imaging
|
- Diagnostic Test: Cardiac Magnetic Resonance Imaging
|
Observational
|
|
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Beijing Anzhen Hospital
- China-Japan Friendship Hospital
- (and 3 more...)
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- All-cause death
- Cardiovascular death
- Heart Transplantation
- (and 5 more...)
|
500 |
All |
18 Years to 60 Years (Adult) |
NCT03096678 |
LBBB001 |
|
January 1, 2010 |
December 31, 2020 |
December 31, 2025 |
March 30, 2017 |
April 11, 2017 |
|
- Fuwai Hospital
Beijing, Beijing, China
|
|
Create an RSS feed from your search for:
Download the search results for: